Augmentation treatment in major depressive disorder: focus on aripiprazole

J Craig Nelson1, Andrei Pikalov2, Robert M Berman31University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USAAbstract: Major depressive disorder (MDD) is a disabling psychiatric condition for wh...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	J Craig Nelson, Andrei Pikalov, Robert M Berman
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/1f8926cba5e74c31913e82fdf0ee37fb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1f8926cba5e74c31913e82fdf0ee37fb
record_format	dspace
spelling	oai:doaj.org-article:1f8926cba5e74c31913e82fdf0ee37fb2021-12-02T02:16:19ZAugmentation treatment in major depressive disorder: focus on aripiprazole1176-63281178-2021https://doaj.org/article/1f8926cba5e74c31913e82fdf0ee37fb2008-08-01T00:00:00Zhttp://www.dovepress.com/augmentation-treatment-in-major-depressive-disorder-focus-on-aripipraz-a1974https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021J Craig Nelson1, Andrei Pikalov2, Robert M Berman31University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USAAbstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.Keywords: major depression, antipsychotic, mood disorder, aripiprazole J Craig NelsonAndrei PikalovRobert M BermanDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 5, Pp 937-948 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 J Craig Nelson Andrei Pikalov Robert M Berman Augmentation treatment in major depressive disorder: focus on aripiprazole
description	J Craig Nelson1, Andrei Pikalov2, Robert M Berman31University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USAAbstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.Keywords: major depression, antipsychotic, mood disorder, aripiprazole
format	article
author	J Craig Nelson Andrei Pikalov Robert M Berman
author_facet	J Craig Nelson Andrei Pikalov Robert M Berman
author_sort	J Craig Nelson
title	Augmentation treatment in major depressive disorder: focus on aripiprazole
title_short	Augmentation treatment in major depressive disorder: focus on aripiprazole
title_full	Augmentation treatment in major depressive disorder: focus on aripiprazole
title_fullStr	Augmentation treatment in major depressive disorder: focus on aripiprazole
title_full_unstemmed	Augmentation treatment in major depressive disorder: focus on aripiprazole
title_sort	augmentation treatment in major depressive disorder: focus on aripiprazole
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/1f8926cba5e74c31913e82fdf0ee37fb
work_keys_str_mv	AT jcraignelson augmentationtreatmentinmajordepressivedisorderfocusonaripiprazole AT andreipikalov augmentationtreatmentinmajordepressivedisorderfocusonaripiprazole AT robertmberman augmentationtreatmentinmajordepressivedisorderfocusonaripiprazole
_version_	1718402578262261760

Augmentation treatment in major depressive disorder: focus on aripiprazole

Ejemplares similares